The National Workers’ Compensation and Disability Conference & Expo (NWCDC) is the only national conference devoted to workers’ compensation and disability management professionals. This conference also features the largest expo in the workers’ compensation industry. Mitchell | Genex | Coventry will have a dynamic exhibit display on the show floor at booth #527 and is happy to be a returning sponsor for this years’ conference. Please contact your Mitchell | Genex | Coventry representative for more information on this private event.
More stories
COVID-19 P&C Industry Update: Regulations, Telemedicine, Access to Care and Testing
As the COVID-19 pandemic has continued, the P&C industry is undergoing many changes, including COVID-19 regulatory changes, telemedicine updates and more.
Accelerating the Shift to Virtual Claims
How is COVID-19 driving adoption of virtual claims handling as the 'new' preferred method of inspection?
Impact of Masks on the Deaf Community
While everyone has been affected by the COVID-19 pandemic in one way or another, the deafblind community has been affected in a detrimental way that most people may not have considered. With the already existing communication challenges, wearing masks has added yet another complicated barrier to communication between hearing and hearing impaired, hard of hearing, deaf and deafblind people.
CEO Alex Sun Introduces Mitchell’s 2nd Quarter 2020 Industry Trends Report
Mitchell leaders report on the impact of COVID-19, the resulting operational and regulatory changes and current industry data trends.
Webinar: Five Tips to Prevent Remote Employee Injuries
Working from home shouldn't be painful,
Opioid Trends Continue to Decline in 2019
First Script saw continued decreasing opioid trends across our retail and mail-order programs in 2019, even while overall prescription trends saw a slight upward shift in utilization per claim and cost per claim. Even with these changes, opioids remain the #1 therapeutic class by usage and cost, however, 2019 marked the largest reduction of the last 5 years in the percentage of opioid scripts with greater than or equal to 90 MED.